What CMS’s prior-authorization push could mean for coverage delays

ByBrian “Weence” Bateman

CMS is proposing new prior-authorization rules for drugs that could shorten waits, improve denial notices, and expand electronic processing across Medicare Advantage, Medicaid, CHIP, and federally facilitated ACA marketplace plans. Some changes are already in motion, but the drug-related requirements would not take effect until 2027 unless CMS finalizes and implements the rule.

The biggest practical takeaway: CMS wants to make prior authorization faster and more transparent for drugs, but this is still a proposal, not final law. If finalized, the changes could affect Medicare Advantage, Medicaid, CHIP, and federally facilitated ACA marketplace plans, while leaving people with different experiences depending on their plan, state, and provider system. CMS’s proposed compliance date for the drug-related changes is October 1, 2027. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-rule))

CMS also announced on May 13 that 29 health systems, EHR vendors, physician practices, networks, and digital health developers have signed on as early adopters for electronic prior authorization work. That effort is meant to help the system prepare for the 2027 requirements, but it does not replace the rulemaking process. ([cms.gov](https://www.cms.gov/newsroom/press-releases/cms-announces-early-adopters-advance-solutions-electronic-prior-authorization-accelerating-momentum))

What prior authorization is — and why people care

Prior authorization is an insurer’s approval step before it will cover certain medicines or services. Supporters say it can help manage costs and check whether care fits coverage rules. Patients and clinicians often see it as a source of delay, paperwork, and, sometimes, denials. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-rule))

For patients, the stakes are practical: a delayed medication start, a refill gap, or extra back-and-forth between a doctor’s office and a plan. CMS is trying to reduce that friction by pushing more of the process into standard electronic systems. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-rule))

What CMS is proposing for drugs

On April 10, CMS proposed extending prior-authorization requirements to drugs in ways that build on its 2024 interoperability rule. The proposal would require impacted payers to support electronic prior authorization for drugs, align decision deadlines across programs, and add more transparency about denials and reporting. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-rule))

CMS says the proposal would generally require drug-related decisions no later than 24 hours for certain Medicaid and CHIP requests and no later than 72 hours for standard requests and 24 hours for expedited requests in federally facilitated marketplace plans. CMS also proposes that plans provide a specific reason when a drug request is denied. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-rule))

Which plans are in scope

The proposal is aimed at Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and qualified health plans on the federally facilitated exchanges. CMS also says it is proposing to add small-group plans on the federally facilitated SHOP exchanges. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-rule))

That said, coverage rules still vary. Even if CMS standardizes parts of the process, patients may still face different prior-authorization rules, turnaround times, and appeals paths depending on the plan they have and the state where they live. KFF’s survey of Medicaid managed care policies found substantial state variation in decision timeframes, denial notices, and review processes. ([kff.org](https://www.kff.org/medicaid/prior-authorization-process-policies-in-medicaid-managed-care-findings-from-a-survey-of-state-medicaid-programs/))

What is already in force

CMS’s 2024 final rule already requires impacted payers to implement a Prior Authorization API for non-drug items and services. Those APIs must communicate whether a request is approved, denied with a specific reason, or needs more information, and that requirement begins January 1, 2027. The rule also set public reporting requirements and a 72-hour/7-day decision framework for many non-drug requests. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f))

The new drug proposal would extend similar ideas to medications, but those requirements still need to be finalized before they can take effect. CMS’s proposed drug-related compliance date is October 1, 2027. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-rule))

Why the timing matters

CMS’s May 13 announcement on early adopters suggests the agency wants the health system to start testing the technical side of prior authorization now, even before final requirements arrive. In other words, this is part policy change and part infrastructure change. ([cms.gov](https://www.cms.gov/newsroom/press-releases/cms-announces-early-adopters-advance-solutions-electronic-prior-authorization-accelerating-momentum))

KFF’s recent analysis shows why that matters for patients: Medicare Advantage insurers processed nearly 53 million prior authorization requests in 2024, and 4.1 million were denied in full or in part. KFF also noted that Medicare Advantage plans process far more prior authorization requests than traditional Medicare, and that CMS is piloting more detailed reporting. ([kff.org](https://www.kff.org/medicare/medicare-advantage-insurers-made-nearly-53-million-prior-authorization-determinations-in-2024/))

What remains uncertain

For now, the proposal could still change before it is finalized. CMS will need to decide which details stay, which get revised, and how quickly plans, states, and health systems can adapt their software and workflows. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-rule))

Even after a final rule, patients may still see different results because prior authorization depends on the plan, the service, the state, and how quickly a provider can submit the needed records. The proposed rule is meant to standardize the process, not eliminate every prior-authorization requirement. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-rule))

What readers can do now

If you are dealing with a prior-authorization problem now, save every notice, denial letter, and appeal deadline. Ask the plan for the specific reason for a denial, and ask your clinician’s office whether they can submit supporting records or request a peer-to-peer review. CMS’s current rule already requires a specific denial reason for many non-drug prior authorization decisions, and the proposed drug rule would extend similar transparency to more cases if finalized. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-prior-authorization-final-rule-cms-0057-f))

If a medication delay could be dangerous or cause a serious setback, contact your clinician promptly. If you think a delay is creating an urgent medical problem, seek urgent or emergency care rather than waiting on the insurer’s process.

For people on Medicare, Medicaid, CHIP, or an ACA marketplace plan, the most useful next step is often to check the exact plan rules and appeal rights, because those can differ even within the same program. ([cms.gov](https://www.cms.gov/newsroom/fact-sheets/2026-cms-interoperability-standards-prior-authorization-drugs-proposed-rule))

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.

Related

Brian “Weence” Bateman is a health and medical writer who covers public health updates, healthcare policy, and medical developments affecting communities across the United States. He works closely with dentists and healthcare providers and focuses on making complex medical information clear, accurate, and useful for everyday readers.